Što je zemlja siromašnija i neobrazovanija, ljudi se manje cijepe

Također, jedno veliko istraživanje objavljeno u časopisu Brain, Behavior, and Immunity pokazalo je da su ljudi koji odbijaju cijepljenje u prosjeku manjih kognitivnih sposobnosti.

U prilog gore navedenom govori i tablica (dolje) u kojoj se prilično jasno vidi korelacija između cijepljenja i čimbenika koji su inače međusobno povezani - razina obrazovnih postignuća, BDP-a po glavi stanovnika i indeksa percipirane korupcije.

Sve zemlje koje imaju višu procijepljenost od Hrvatske imaju također i viši BDP po glavi stanovnika, bolje rezultate na testovima PISA i nižu percipiranu korupciju. Obratno vrijedi za zemlje koje su slabije procijepljene.

Najobičniji teror.
Svaki iskompleksirani manijak koji žudi za soljenjem pameti drugima, za maltretiranjem ljudi s kojima se ne slaže i to pomoću alata državne prisile, sada je došao na svoje - vlast mu daje načina da zadovolji niske strasti iživljavanjem nad onima koji odbijaju cjepivo.

Necjepiše postaju naporne sa svojim teorijama, a u stvarnom zivotu su jako agresivni i bezobrazni kad su u drustvu cijepljenih ljudi.

Ubilo ih cjepivo?

Imam odredjenih kardio-vaskularnih problema zbog kojih sam i jutros radio ekg, sutra da bude sta, reci ce pojedinci to je od cjepiva, bez obzira sto imam te probleme zadnjih 7 godina.

Da ti je šta bilo prije samo 1 godine, ti bi bio žrtva korona virusa.

A neki bi se smijali jer je Bakić pogriješio.

Recimo da imas ostecena pluca i visok tlak, i onda se dodatno razbolis od covida i umres, od cega si umro?

prije godinu dana

Pfizer strikes deal to allow generic versions of its Covid pill for world’s poor
Under the licensing agreement, Pfizer will not receive royalties from the manufacturers, making the treatment cheaper

Wed 17 Nov 2021 01.24 GMT

US pharmaceutical giant Pfizer has announced a deal to make its prospective antiviral Covid-19 pill available more cheaply in the world’s least-wealthy countries.

Pfizer will allow generic manufacturers to supply its promising Paxlovid pill to 95 low-and middle-income nations covering about 53% of the world’s population, the company said in a statement on Tuesday.

Under the licensing agreement deal struck with the global Medicines Patent Pool (MPP), Pfizer - which also produces one of the most widely used Covid vaccines with German lab BioNTech - will not receive royalties from the manufacturers, making the treatment cheaper.

The agreement is subject to the oral antiviral medication passing ongoing trials and regulatory approval.

Interim data from ongoing trials demonstrated an 89% reduction in the risk of Covid-19-related hospitalisation or death compared to a placebo, in non-hospitalised high-risk adults with Covid-19 within three days of symptom onset, said Pfizer.

Similar results were seen within five days of symptom onset, it added.

The Geneva-based MPP is a United Nations-backed international organisation that works to facilitate the development of medicines for low-and middle-income nations.
If approved, the pill could be on the market in “a matter of months”, MPP policy chief Esteban Burrone told Agence France-Presse.
Pfizer also said Tuesday that it was seeking an emergency use authorisation, or EUA, in the US for the Covid pill.

Pfizer will forego royalties on sales in all countries covered by the agreement while Covid-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
Paxlovid, or PF-07321332, is an investigational antiviral therapy designed to block the activity of the Sars-CoV-2-3CL protease - an enzyme that the coronavirus needs to replicate.
Taking it together with a low dose of HIV medicine ritonavir helps slow the breakdown of PF-07321332. It therefore remains active in the body for a longer period at a high concentration, to help combat the virus.

“We believe oral antiviral treatments can play a vital role in reducing the severity of Covid-19 infections, decreasing the strain on our healthcare systems and saving lives,” said Pfizer chairman and chief executive Albert Bourla.
While a multitude of vaccines have been rolled out in the pandemic, the hunt for treatments for those who have already caught the disease has not been as fruitful.

“This licence is so important because, if authorised or approved, this oral drug is particularly well-suited for low-and middle-income countries and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic,” Charles Gore, Executive Director of MPP, said in a statement on Tuesday.

Potential sublicensees have until 6 December to register an expression of interest.
The announcement comes after the MPP signed a similar voluntary licensing deal with Pfizer’s US rivals Merck & Co last month for its investigational oral antiviral medicine molnupiravir.
Subject to regulatory approval, the deal will help create broad access to molnupiravir in 105 low-and middle-income countries.

Pills are easier to make than vaccines, do not require a cold chain for delivery and can be self-administered by the patient.
Pricing for the Pfizer pill has not yet been set, with Doctors Without Borders (MSF) suggesting it might cost about $700 per Pfizer treatment course, in line with molnupiravir.
The medical charity said it was disheartened by the deal, saying restrictive voluntary licences were no substitute for guaranteed global access to Covid tools to bring the pandemic under control.